Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
In-depth stories
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
Poster selection
Tafasitamab-lenalidomide for relapsed/refractory DLBCL: real-world data from the GELTAMO study
December 26, 2024
During ASH 2024, Prof Dr Antonio Gutierrez (University Hospital Son Espases, Palma de Mallorca, Spain) presented updated results of the GELTAMO study evaluating the real-life efficacy and safety of tafa-len
Efficacy and safety of selinexor-pomalidomide-dexamethasone in patients with released/refractory multiple myeloma
December 26, 2024
Dr Muhamed Baljevic is a haematologist at the Vanderbilt University Medical Center, in Nashville, Tennessee (USA). During ASH 2024 he presented data from a phase 1b/2 study evaluating the combination
Adding blinatumomab to consolidation therapy in older newly-diagnosed patients with Philadelphia-negative B-ALL
December 26, 2024
During ASH 2024, Dr Nikolai Podoltsev from the Yale School of Medicine in New Haven, CT (USA) presented the results of a subgroup analysis of this trial looking into the
Isa-VRd in transplant-ineligible patients with newly diagnosed multiple myeloma and high-risk features
December 26, 2024
During ASH 2024, Prof Xavier Leleu (Hôpital La Mileterie, CHU Poitiers, Poitiers, France) presented updated results of this trial looking at the efficacy results in function of the risk profile
Isatuximab-lenalidomide-bortezomib and low-dose dexamethasone: an effective steroid sparing regimen for transplant-ineligible MM
December 26, 2024
The phase II REST study is evaluating a steroid-sparing regimen consisting of isatuximab, lenalidomide, bortezomib and a limited dose of dexamethasone (Isa-VRd) as a first line treatment for transplant ineligible
Momelotinib for the treatment of myelofibrosis: real-world data
December 24, 2024
Dr Alexandros Rampotas presented a poster with real-world data on the use of momelotinib in patients with myelofibrosis. The analysis included a total of 119 myelofibrosis patients who received momelotinib
Lower response rates to cevostamab in triple-class refractory multiple myeloma patients who previously received a bispecific antibody
December 24, 2024
During ASH 2024, Prof Michel Delforge, haematologist at the University Hospitals Leuven (Belgium) presented updated results of this trial with a specific focus on the impact of the type of
Predictive value of D-dimer concentrations in patients on long-term direct oral anticoagulation after a venous thrombo-embolism
December 24, 2024
During the 2024 annual ASH meeting, Prof Cédric Hermans, shared the results of an analysis looking into the levels and predictive potential of D-Dimers in patients on long-term anticoagulation with